Plasma biomarker progression across the Alzheimer's disease amyloid beta and tau positron emission tomography trajectories - PubMed
3 months ago
- #Alzheimer's disease
- #biomarkers
- #PET imaging
- Plasma biomarkers were studied to detect amyloid beta (Aβ) and tau in Alzheimer's disease using PET imaging.
- Tau phosphorylated at threonine 217 (pTau217) showed significant increases across Aβ and tau levels.
- pTau217/Aβ42 ratio had high accuracy in predicting Aβ status with minimal intermediate zone participants.
- Biomarkers demonstrated utility in predicting Aβ and tau PET but had varied responses to Aβ and tau aggregation.
- Several authors disclosed conflicts of interest, including affiliations with pharmaceutical companies.